drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Off-the-shelf (allogeneic) CD7-directed chimeric antigen receptor T-cell (CAR-T) therapy; single intravenous dose of 2 x 10^8 CAR+ T cells engineered to express a CD7-binding CAR with CD3zeta/co-stimulatory signaling domains, inducing cytotoxic killing of CD7+ malignant T cells in relapsed/refractory T-ALL/LBL.
nci_thesaurus_concept_id
C200796
nci_thesaurus_definition
A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD7 CAR-T cells RD13-02 specifically target and kill CD7-expressing tumor cells. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf (allogeneic) T cells engineered to express a CD7-binding chimeric antigen receptor with CD3zeta and costimulatory signaling domains. Upon binding CD7 on malignant T cells, the CAR triggers T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxicity, leading to selective killing of CD7-positive leukemic/lymphoblastic cells.
drug_name
RD13-02
nct_id_drug_ref
NCT05923541